Related Experiment Videos
Isotopic evaluation and therapy in patients with malignant endocrine disease
1Department of Nuclear Medicine, Southampton University Hospitals NHS Trust, Tremona Road, Southampton, SO16 6YD, UK.
Abstract:
The contribution of nuclear medicine to the diagnosis and treatment of endocrine malignancy is increasing. Advances in molecular biology offer new opportunities for tumour targeting via surface receptor recognition and tumour-specific metabolic markers. Imaging the biodistribution of these markers allows quantitative, in vivo characterization of tumour function. There is growing interest in the therapeutic potential of nuclear medicine targeting, substituting therapeutic beta-emitting radionuclides for the gamma-emitters used in diagnostic imaging. Limited clinical experience supports the rationale of this approach in patients with inoperable or disseminated disease and controlled trials are in progress. This chapter outlines the place of nuclear medicine techniques in the routine management of endocrine malignancy and explores areas for further development.
Insights
Nuclear medicine is increasingly vital for diagnosing and treating endocrine cancers. New molecular techniques enable targeted therapies, offering hope for advanced or inoperable disease.
Area of Science:
- Oncology
- Nuclear Medicine
- Molecular Biology
Background:
- Nuclear medicine's role in endocrine malignancy diagnosis and treatment is expanding.
- Molecular biology advances enable novel tumor targeting strategies.
Purpose of the Study:
- To outline the current role of nuclear medicine in endocrine malignancy management.
- To explore future developments in nuclear medicine for endocrine cancers.
Main Methods:
- Utilizing molecular biology for tumor targeting via receptor recognition and metabolic markers.
- Imaging biodistribution of markers for in vivo tumor function characterization.
- Investigating therapeutic potential by substituting beta-emitting radionuclides for gamma-emitters.
Main Results:
- Growing interest in therapeutic nuclear medicine applications.
- Limited clinical experience suggests potential for inoperable or disseminated disease.
- Controlled trials are underway to evaluate therapeutic approaches.
Conclusions:
- Nuclear medicine offers promising avenues for endocrine malignancy diagnosis and therapy.
- Further research and clinical trials are essential to realize its full potential.